Research graph
References from Direct Oral Anticoagulant–Calibrated Heparin <scp>LRT</scp> Assay as a Rapid Alternative to an Anti‐Factor Xa Assay for Measuring Apixaban, Edoxaban, and Rivaroxaban in Patients With Non‐Valvular Atrial Fibrillation. Local targets link to admitted publications; unresolved targets remain external evidence.
In a Nutshell: Testing DOAC Levels—When, Why and What It Means?
10.1111/bjh.70313 · 2026 · External reference
Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions
10.1111/ijlh.14483 · 2026 · External reference
An Update on Laboratory Assessment for Direct Oral Anticoagulants
10.1111/ijlh.12992 · 2019 · External reference
Monitoring of Direct Oral Anticoagulants Plasma Levels for Secondary Stroke Prevention
10.1111/jth.15677 · 2022 · External reference
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
10.1055/s-0038-1627480 · 2018 · External reference
2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
10.1055/a-1450-8178 · 2021 · External reference
Laboratory Testing in Patients Treated With Direct Oral Anticoagulants: A Practical Guide for Clinicians
10.1111/jth.13912 · 2018 · External reference
Usefulness of Heparin Calibrated Anti‐Xa Activity to Assess Anticoagulant Activity of Apixaban and Rivaroxaban in Emergency Patients Scheduled for Acute Interventions
10.3390/jcm12216785 · 2023 · External reference
Using a Low‐Molecular Weight Heparin‐Calibrated Anti‐Factor Xa Assay to Assess the Concentration of Apixaban and Rivaroxaban
10.1111/ijlh.13692 · 2022 · External reference
10.1515/cclm‐2026‐0026
10.1515/cclm‐2026‐0026 · External reference
2020 ESC Guidelines for the Diagnosis and Management of Atrial Fibrillation
10.1093/eurheartj/ehaa612 · 2021 · External reference
2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary
10.1055/s-0041-1739411 · 2022 · External reference
